MARKET CLOSE: NZ shares rise as vaccine trial boosts global sentiment

MARKET CLOSE: NZ shares rise as vaccine trial boosts global sentiment
Dan Brunskill
New Zealand shares rose for a third day as investors welcomed interim results of a covid-19 vaccine trial which showed a positive immune response to the virus. The S&P/NZX 50 Index rose 116.38 points, or 1 percent, to 11,610.52. Within the index, 34 stocks rose and 16 fell. Turnover was $186.9 million. The experimental vaccine, developed by biotech company Moderna, safely induced an immune response against covid-19 in all 45 participants, researchers reported in The New England Journal of Medicine. Moderna has now announced that a phase 3...

More Markets

NZ sharemarket continues sliding, down 0.5%
Markets Market close

NZ sharemarket continues sliding, down 0.5%

The S&P/NZX 50 Index closed at 12,692.72, down 68.47 points or 0.54%.

Graham Skellern 12 Dec 2024
Spark sells remaining Connexa stake for $314m
Markets

Spark sells remaining Connexa stake for $314m

The sale will result in a $70m gain on telco's books.

Ben Moore 12 Dec 2024
Zespri on track for 'moderate increase' in volume next year
Primary Sector

Zespri on track for 'moderate increase' in volume next year

Zespri's producer vote to expand global supply passed this week.

Riley Kennedy 12 Dec 2024
Neal Barclay to exit Meridian as CEO
Markets

Neal Barclay to exit Meridian as CEO

Current CFO Mike Roan will take Barclay's spot atop Meridian.

Staff reporters 12 Dec 2024